Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Vortioxetine in MDD extension study
NCT00694304Phase 3Completed
- Sponsor
- Lundbeck
- Start
- May 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started May 2008; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00694304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694304.